Archive · 16 Sep 2025
India Revokes Novartis' Patent for Heart Failure Drug
The Indian Patent Office took away Novartis' patent for Vymada, a heart failure medicine.
This means other companies can now make and sell the medicine in India.
The Patent Office decided that the new patent didn't show enough improvement over the existing formulation.
This ruling aims to make the medicine more affordable in India.
Novartis can still challenge the decision in court.
India revoked the patent for Novartis' heart failure drug, Vymada.
The Indian Patent Office cited lack of novelty as the reason.
The decision opens the market for affordable generic versions of the drug.
The Indian Pharmaceutical Alliance opposed the patent.
Novartis can appeal the decision.
- Who
- Indian Patent Office and Novartis
- What
- Revoked Novartis' patent for Vymada, allowing generics
- When
- September 2025
- Where
- India
- Why
- Due to lack of novelty and therapeutic advantage.
Novartis
Generic Drug Manufacturers and Patients
Patent Validity
Novartis
Believed the patent for the crystalline complex was valid.
Generic Drug Manufacturers and Patients
Contended the patent lacked novelty and did not offer a significant therapeutic advantage.
- Drug
- Vymada (Entresto internationally)
- Active Ingredients
- Sacubitril and Valsartan
- Patent Revocation Date
- September 12, 2025
- Patent Holder
- Novartis
- Reason for Revocation
- Lack of novelty
